Citations

Clear

95 citation(s) found for "Diamond, M P".

SARC037: Phase II results of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in patients (pts) with relapsed/refractory Ewing sarcoma (ES).
Grohar, Patrick J. , Glod, John , Wedekind, Mary Frances Frances, DuBois, Steven G. , Laetsch, Theodore W. , Diamond, Mark S., Navid, Fariba , Widemann, Brigitte C. , Ballman, Karla V. , Heise, Rachel S. , Mascarenhas, Leo , Wedekind, Mary Frances , Gedminas, Jenna Marie , Maki, Robert G. , Crompton, Brian D. , Figg, William D. , Bagatell, Rochelle , Roberts, Ryan D. , Reinke, Denise K. , Chugh, Rashmi

Mayo Clinic

Journal of Clinical Oncology | June 13, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 11508-11508

10.1200/jco.2024.42.16_suppl.11508 Get It

11508 Background: Trabectedin(T) is a marine-derived minor groove DNA binding compound that alters transcription factor activity. Preclinical data suggests that T suppresses the oncogenic driver of ES, EWS::FLI1. This suppression requires a threshold concentration of T and is potentiated by low doses of Irinotecan(I). Preliminary clinical activity and reversal of the EWS::FLI1 transcriptome was seen in patients (pts) in the phase I portion of SARC037. Here we report the phase II results of T with I at the recommended dose in pts with relapsed/refractory ES. Methods: In this open-label multicenter study, T was given at 1 mg/m2 as a 1-h infusion on day(D)1 with I at 25 mg/m2 intravenously on D2 and D4 of a 21D cycle. Key eligibility criteria were EWS::FLI1 fusion transcript, age ≥6 years, ECOG ≤2, adequate organ function, and willing to have a research biopsy if safely accessible. The primary objective was to determine the objective response rate (ORR) assessed by RECIST v1.1. Secondary objectives were progression-free survival (PFS), duration of response (DOR), and safety. This study used a Simon two-stage design that required 4 or more responses (CR or PR) at the final analysis to establish treatment activity. Results: 18 pts enrolled from 12/2022-12/2023 across 6 sites, 8F/10M, median age 21y (9-43). Pts had a median of 3 (1-7) prior therapy lines, including I in 67% of pts. Of 16 pts evaluable for response at the cutoff date, 5 pts had a PR, and 2 pts had SD. Two pts have evaluations pending and two pts were removed for toxicity before the first evaluation. Median time to response was 2.6 months(m), 6-month PFS was 37.7% (95% CI 18.3%, 77.7%), and all responses were sustained at the time of data cutoff at 10.4+, 7.5+, 5.5+, 5.0+ and 4.6+ m. There were no G5 AEs. Most pts had molecular profiling, translocation testing, as well as ctDNA collection, quantitation, and analysis. A subset of pts had pre- and post-treatment biopsies for RNA sequencing and evaluation of the impact of drug exposure on the EWS::FLI1 transcriptome. Conclusions: T+I exhibited anti-tumor activity in heavily pretreated pts with ES and met its prespecified ORR with 5 PRs in 16 evaluable patients, all of which are ongoing at data cutoff. There were no unexpected safety signals. The combination of T given as a 1h infusion and low-dose I demonstrated meaningful clinical benefit and is worthy of further study in ES pts. Analysis of biological correlates is ongoing. Clinical trial information: NCT04067115 .
Integrating 4 Methods (In4M) to evaluate physical function in patients with cancer: Results of a comprehensive digital health study.
Thanarajasingam, Gita , Bhatnagar, Vishal , Diamond, Matthew, Jones, Lee , Power, Bradford, Ruddy, Kathryn J. , Tarver, Michelle E. , Gross, Cary P. , Dueck, Amylou C. , Brown, Abbie, Cathcart-Rake, Elizabeth , Diamond, Matthew, Faust, Louis , Fiero, Mallorie H. , Huntington, Scott F. , Jeffery, Molly Moore , Paludo, Jonas , Ross, Joseph S. , Mougalian, Sarah S. , Wood, William A. , Kluetz, Paul Gustav

Mayo Clinic

Journal of Clinical Oncology | June 4, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 1564-1564

10.1200/jco.2024.42.16_suppl.1564 Get It

1564 Background: Physical function (PF) is a core outcome in cancer trials that can inform treatment tolerability. PF can be assessed across modalities including by patient (pt) report, clinician (clin) report, performance tests and digital sensors. The optimal approach for PF measurement has not been defined. Methods: In4M is a prospective observational study evaluating PF in pts initiating chemotherapy for breast cancer or lymphoma followed over 9 months. We used an electronic platform (Hugo) to aggregate serially assessed pt-reported PF, clin- and pt-reported ECOG performance status (PS), 6-minute walk test (6MWT) and wearable (Fitbit) data. We evaluated feasibility in all pts; associations among PF measures and the ability of PF measures to detect change were evaluated in pts with both baseline (BL) and 3-month (3M) data. We used Pearson correlations to assess the relationship of average daily steps with measures of PF. To assess change, we compared each PF measure from BL to 3M using a 2-sided α=.05 paired t-test. Results: Of the208 pts enrolled, 193 (93%) and 159 (76%) completed surveys, and 121 (58%) and 124 (60%) provided wearable data (evaluable: ≥1 day data) at BL and 3M, respectively. When requiring a stringent BL with 4+ days of data with ≥1 weekend day to be evaluable, 88 (42%) and 120 (58%) provided wearable data at BL and 3M. At both BL and 3M, pt-reported PF was generally more highly correlated with wearable-derived daily steps than clin-reported PF and 6MWT were (Table). Significant declines in PF were observed for pt- and clin-reported PF (all p<0.05), but not other modalities. Conclusions: Longitudinalassessment of multi-modal PF data including pragmatic wearable data collection was feasible in pts receiving chemotherapy. Pt-reported PF was the only modality that was both correlated with step count and able to detect change. Additional wearable metrics, correlations among PF measurements and outcomes, and clinically meaningful change scores will be reported. Optimal PF measurement may improve future reporting of treatment tolerability. Clinical trial information: NCT05214144 . [Table: see text]
A Prospective, Multi-Center, Open-Label Assessment of Efficacy and Safety of the Quanta Dialysis System for Home Hemodialysis
Hussein, Wael F. , Atray, Naveen K., Bett, Doreen W., Chan, Christopher T. , Diamond, Matthew J., Green, Gopa B. , Karl, Bethany E., Kattah, Andrea G. , Seek, Melvin, Watnick, Suzanne , Weinhandl, Eric D. , Whitlock, Reid , Bismarck, Lisa, Gorbe, Kelley L., Komenda, Paul , Gupta, Nupur

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 34 | Issue: 11S | Pages: 177-177

10.1681/asn.20233411s1177a Get It

Utilization and perspectives of weight loss medications in pediatric metabolic dysfunction‐associated steatotic liver disease
Ibrahim, Samar H. , Ramirez, Charina M. , Amin, Saista Asif, Diamond, Tamir , Ibrahim, Samar H , Kehar, Mohit , Amin, Saista Asif, Mohammad, Saeed

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | May 3, 2024 | Volume: 79 | Issue: 3 | Pages: 661-666

10.1002/jpn3.12236 | PMID 38698664 Get It

AbstractMetabolic dysfunction‐associated steatotic liver disease (MASLD) is increasing globally in pediatric populations. Currently, MASLD management primarily relies on lifestyle interventions, which pose challenges in sustaining long‐term weight loss. This study investigated the use of weight loss medications in MASLD care through an international survey of 166 pediatric gastroenterologists and hepatologists. The results indicated a notable interest in weight loss medications, with 38% of practitioners considering or using them, particularly glucagon‐like peptide‐1 receptor agonists. However, the survey also revealed a tendency among clinicians to refer patients to specialists, emphasizing the potential gap between acknowledgment and prescription practices. Challenges include the lack of guidelines and uncertainty regarding side effects. The study highlights a pressing need for education, with over 90% of the respondents expressing an interest. Our study highlights the current management of MASLD, the potential role of pharmacotherapy, and highlights avenues for improved care and education in this dynamic field.
Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy
Friedman, Joshua, Yabe, Mariko , Petrova‐Drus, Kseniya , Pulitzer, Melissa , Busam, Klaus J. , Rampal, Raajit K. , Ulaner, Gary A. , Reddy, Ryan , Yeh, Randy , Rotemberg, Veronica , Hershkovitz‐Rokah, Oshrat , Shpilberg, Ofer , Abeykoon, Jithma P. , Fidai, Shiraz , Gannamani, Vedavyas, Zia, Maryam, Panageas, Katherine S. , Rosenblum, Marc K. , Durham, Benjamin H. , Reiner, Anne S , Mazor, Roei D , Hershkovitz-Rokah, Oshrat , Goyal, Guarav , Abeykoon, Jithma P , Diamond, Eli L , Ulaner, Gary , Reiner, Anne S. , Doǧan, Ahmet , Francis, Jasmine H. , Hatzoglou, Vaios , Lacouture, Mario E. , Mazor, Roei David , Goyal, Gaurav , Go, Ronald S. , Rech, Karen L. , Morlote, Diana M. , Abdel‐Wahab, Omar , Diamond, Eli L.

Mayo Clinic

British Journal of Haematology | April 13, 2024 | Volume: 205 | Issue: 1 | Pages: 127-137

10.1111/bjh.19462 | PMID 38613141 Get It

Summary Histiocytic neoplasms are diverse clonal haematopoietic disorders, and clinical disease is mediated by tumorous infiltration as well as uncontrolled systemic inflammation. Individual subtypes include Langerhans cell histiocytosis (LCH), Rosai–Dorfman–Destombes disease (RDD) and Erdheim–Chester disease (ECD), and these have been characterized with respect to clinical phenotypes, driver mutations and treatment paradigms. Less is known about patients with mixed histiocytic neoplasms (MXH), that is two or more coexisting disorders. This international collaboration examined patients with biopsy‐proven MXH with respect to component disease subtypes, oncogenic driver mutations and responses to conventional (chemotherapeutic or immunosuppressive) versus targeted (BRAF or MEK inhibitor) therapies. Twenty‐seven patients were studied with ECD/LCH (19/27), ECD/RDD (6/27), RDD/LCH (1/27) and ECD/RDD/LCH (1/27). Mutations previously undescribed in MXH were identified, including KRAS, MAP2K2, MAPK3, non‐V600‐BRAF, RAF1 and a BICD2‐BRAF fusion. A repeated‐measure generalized estimating equation demonstrated that targeted treatment was statistically significantly (1) more likely to result in a complete response (CR), partial response (PR) or stable disease (SD) (odds ratio [OR]: 17.34, 95% CI: 2.19–137.00, p = 0.007), and (2) less likely to result in progression (OR: 0.08, 95% CI: 0.03–0.23, p < 0.0001). Histiocytic neoplasms represent an entity with underappreciated clinical and molecular diversity, poor responsiveness to conventional therapy and exquisite sensitivity to targeted therapy.
Pre-existing Immunocompromising Conditions and Outcomes of Acute COVID-19 Patients Admitted for Pediatric Intensive Care
Rowan, Courtney M. , Zambrano, Laura D. , Newhams, Margaret M. , Kücükak, Suden, McNamara, Elizabeth R, Mack, Elizabeth H. , Fitzgerald, Julie C. , Irby, Katherine , Schuster, Jennifer E. , Kong, Michele, Loftis, Laura L. , Kolmar, Amanda , Babbitt, Christopher , Nofziger, Ryan A. , Hall, Mark W. , Gertz, Shira J. , Zinter, Matt S. , Halasa, Natasha , Bradford, Tamara T. , McLaughlin, Gwenn E., Singh, Aalok R. , Staat, Mary Allen , Coates, Bria M. , Crandall, Hillary R, Maamari, Mia , Havlin, Kevin , Schwarz, Adam J. , Carroll, Christopher L. , Levy, Emily R. , Campbell, Angela P. , Randolph, Adrienne G. , Chou, Janet , Investigators, Overcoming COVID-19, Kong, Michele, Gaspers, Mary Glas , Sanders, Ronald C., Schwarz, Adam J, Harvey, Helen , Port, Emily, Shankman, Sara, Mansour, Rachel, Espinal, Paula S., Tarquinio, Keiko M. , Bhoojhawon, Guru , Sullivan, Janice E, Bradford, Tamara T, Newhams, Margaret M, Chen, Sabrina , Young, Cameron C, Carroll, Ryan W. , Yager, Phoebe H. , Flori, Heidi R. , Johnson, Brandi A., Drapeau, Noelle M., Malloch, Lacy , Martin, Lora, McGraw, Sarah , Schuster, Jennifer E, Cullimore, Melissa L. , Clouser, Katharine N. , Kleinman, Lawrence C. , Horwitz, Steven M. , Kuebler, Joseph D. , Soma, Vijaya L, Doymaz, Sule , Schwartz, Stephanie P, Walker, Tracie C. , Lansell, Amanda , Hall, Mark W. , Burnett, Ryan H., Bush, Jenny L., Carcillo, Joseph A. , Butler, Andrew , Reed, Nelson, Stewart, Laura S , Golchha, Meena, Samperio, Marian, Qurashi, Jacob , Bowens, Cindy , Crandall, Hillary , Smith, Lincoln , Kong, Michele , Martin, Lora , Randolph, Adrienne G , Levy, Emily R , Kong, Michele , Staat, Mary A , Gertz, Shira J , LaBere, Brenna , Young, Cameron C. , Maddux, Aline B. , Kong, Michele, Dapul, Heda , Schwartz, Stephanie P. , Bembea, Melania M. , Cvijanovich, Natalie Z , Hobbs, Charlotte V. , Wellnitz, Kari , Moffitt, Kristin , Investigators, Overcoming COVID-19, Kong, Michele, Typpo, Katri , Schwarz, Adam J, Pannaraj, Pia S. , Giuliano, John S. , Michelson, Kelly Nicole , Sullivan, Janice E, Montgomery, Vicki , Bradford, Tamara T, Graciano, Ana Lía , Newhams, Margaret M, Young, Cameron C, Son, Mary Beth F. , Fernandes, Neil D. , Hume, Janet R. , Behl, Supriya , McGraw, Sarah, Schuster, Jennifer E, Spinella, Philip C. , McCulloh, Russell J. , Li, Simon , Ratner, Adam J. , BIAGAS, KATHERINE V. , Schwartz, Stephanie P, Shein, Steven L. , Bush, Jenny, Thomas, Neal J. , Fink, Ericka L. , Reed, Nelson, Muñoz, Álvaro Coronado , McGuire, John K.

Mayo Clinic

Clinical Infectious Diseases | March 11, 2024 | Volume: 79 | Issue: 2 | Pages: 395-404

10.1093/cid/ciae133 | PMID 38465976 Get It

Abstract Background We aimed to determine if pre-existing immunocompromising conditions (ICCs) were associated with the presentation or outcome of patients with acute coronavirus disease 2019 (COVID-19) admitted for pediatric intensive care. Methods Fifty-five hospitals in 30 US states reported cases through the Overcoming COVID-19 public health surveillance registry. Patients &lt;21 years admitted 12 March 2020–30 December 2021 to the pediatric intensive care unit (PICU) or high-acuity unit for acute COVID-19 were included. Results Of 1274 patients, 105 (8.2%) had an ICC, including 33 (31.4%) hematologic malignancies, 24 (22.9%) primary immunodeficiencies and disorders of hematopoietic cells, 19 (18.1%) nonmalignant organ failure with solid-organ transplantation, 16 (15.2%) solid tumors, and 13 (12.4%) autoimmune disorders. Patients with ICCs were older, had more underlying renal conditions, and had lower white blood cell and platelet counts than those without ICCs, but had similar clinical disease severity upon admission. In-hospital mortality from COVID-19 was higher (11.4% vs 4.6%, P = .005) and hospitalization was longer (P = .01) in patients with ICCs. New major morbidities upon discharge were not different between those with and without ICC (10.5% vs 13.9%, P = .40). In patients with ICCs, bacterial coinfection was more common in those with life-threatening COVID-19. Conclusions In this national case series of patients &lt;21 years of age with acute COVID-19 admitted for intensive care, existence of a prior ICCs were associated with worse clinical outcomes. Reassuringly, most patients with ICCs hospitalized in the PICU for severe acute COVID-19 survived and were discharged home without new severe morbidities.
Genomic Classification and Individualized Prognosis in Multiple Myeloma
Maura, Francesco , Rajanna, Arjun Raj , Ziccheddu, Bachisio , Poos, Alexandra M. , Derkach, Andriy , Maclachlan, Kylee , Durante, Michael , Diamond, Benjamin , Papadimitriou, Marios , Davies, Faith E. , Boyle, Eileen M. , Walker, Brian A. , Hultcrantz, Malin , Silva, Ariosto, Hampton, Oliver , Teer, Jamie K. , Siegel, Erin M. , Bolli, Niccolò , Jackson, Graham , Kaiser, Martin , Cook, Gordon , Kazandjian, Dickran , Stein, Caleb, Chesi, Marta , Bergsagel, Leif, Elias, K. , Goldschmidt, Hartmut , Fenk, Roland , Rhee, Fritz Van, Usmani, Saad Z. , Shain, Kenneth H. , Weinhold, Niels , Bergsagel, P. Leif , Bergsagel, P. Leif , Davies, Faith E , Walker, Brian A , Jackson, Graham H , Pawlyn, Charlotte , Cook, Gordon , Kazandjian, Dickran , Chesi, Marta , Mai, Elias K , Goldschmidt, Hartmut , Weisel, Katja C , Fenk, Roland , Raab, Marc S , van Rhee, Frits , Usmani, Saad , Shain, Kenneth H , Weinhold, Niels , Landgren, C Ola , Bolli, Niccolo' , Boyle, Eileen M , Kaiser, Martin F , Maura, Francesco , Durante, Michael , Maclachlan, Kylee , Derkach, Andriy , Diamond, Benjamin T , Pawlyn, Charlotte , Stein, Caleb, Raab, Marc S. , Morgan, Gareth J. , Landgren, Ola

Mayo Clinic

Journal of Clinical Oncology | January 9, 2024 | Volume: 42 | Issue: 11 | Pages: 1229-1240

10.1200/jco.23.01277 | PMID 38194610 Get It

PURPOSE Outcomes for patients with newly diagnosed multiple myeloma (NDMM) are heterogenous, with overall survival (OS) ranging from months to over 10 years. METHODS To decipher and predict the molecular and clinical heterogeneity of NDMM, we assembled a series of 1,933 patients with available clinical, genomic, and therapeutic data. RESULTS Leveraging a comprehensive catalog of genomic drivers, we identified 12 groups, expanding on previous gene expression–based molecular classifications. To build a model predicting individualized risk in NDMM (IRMMa), we integrated clinical, genomic, and treatment variables. To correct for time-dependent variables, including high-dose melphalan followed by autologous stem-cell transplantation (HDM-ASCT), and maintenance therapy, a multi-state model was designed. The IRMMa model accuracy was significantly higher than all comparator prognostic models, with a c-index for OS of 0.726, compared with International Staging System (ISS; 0.61), revised-ISS (0.572), and R2-ISS (0.625). Integral to model accuracy was 20 genomic features, including 1q21 gain/amp, del 1p, TP53 loss, NSD2 translocations, APOBEC mutational signatures, and copy-number signatures (reflecting the complex structural variant chromothripsis). IRMMa accuracy and superiority compared with other prognostic models were validated on 256 patients enrolled in the GMMG-HD6 (ClinicalTrials.gov identifier: NCT02495922 ) clinical trial. Individualized patient risks were significantly affected across the 12 genomic groups by different treatment strategies (ie, treatment variance), which was used to identify patients for whom HDM-ASCT is particularly effective versus patients for whom the impact is limited. CONCLUSION Integrating clinical, demographic, genomic, and therapeutic data, to our knowledge, we have developed the first individualized risk-prediction model enabling personally tailored therapeutic decisions for patients with NDMM.
Outcomes with MEK Inhibitor Therapy Among Adults with Langerhans Cell Histiocytosis (LCH): A Multi-Institutional Study from the Adult LCH Working Group for the Histiocyte Society
Medina, Aldo Adrian Acosta, Bossert, Dana, Abeykoon, Jithma P. , Amerikanou, Rodothea , Bach, Corrie R. , Hook, C. Christopher , Lang, Min , Petrova‐Drus, Kseniya , Rotemberg, Veronica , Ruan, Gordon , Yabe, Mariko , Zanwar, Saurabh , Goyal, Gaurav , Cao, Xin-Xin , Collin, Matthew , Makras, Polyzois , Abdel‐Wahab, Omar , Bennani, N. Nora , Durham, Benjamin H. , Francis, Jasmine H. , Lang, Min, Lacouture, Mario E. , Rech, Karen L. , Shah, Meera , Young, Jason R. , Go, Ronald S. , Diamond, Eli L.

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 4559-4559

10.1182/blood-2023-184911 Get It

Purpose: The discovery of MAPK/ERK pathway mutations has led to the approval of MEK-inhibitor (MEKi) cobimetinib in histiocytic neoplasms. However, the pivotal clinical trial that led to the approval of cobimetinib included only 4 patients with Langerhans cell histiocytosis (LCH). Therefore, there is a need to define outcomes with MEKi therapy in patients with LCH. We undertook a multi-center collaboration through the Adult LCH Working Group for the Histiocyte Society to address this gap in knowledge. Methods: Adults with LCH who received MEKi therapy were included from five institutions. Objective response rate (ORR) was evaluated using PET/CT criteria, and CT/MRI if PET scan was not available; response categories were categorized into complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Progression-free (PFS) and overall survival (OS) were calculated from the time of targeted therapy initiation. Risk organ disease was defined as liver, spleen, or bone marrow involvement. Results: 25 adults with LCH were included in this study; median age at MEKi initiation 43y (range, 18-85). Most common systems involved at diagnosis were bone (52%), pituitary (44%), and lung (36%). Risk organ involvement was observed in 7 (28%, 6 liver, 1 liver and spleen) and 2 (8%) patients had intra-axial CNS involvement. Median lines of prior therapy received were 2 (range: 1-5), and 4 (16%) patients received MEKi in first-line. MAPK/ERK pathway status was assessed via target capture next generation sequencing (NGS) in 22 (96%) cases. Amongst those who underwent NGS, alterations identified included: BRAF V600E (2/22, 9%), BRAF deletions (11/22 50%), MAP2K1 or MEK mutations (4/22, 18%), and MAPK1 or ERK2 (n=1, 5%). Overall, 5 patients also received BRAF inhibitors (4 patients as first therapy prior to MEKi and 1 concomitantly due to BRAF V600E positive melanoma). Specific MEKi agents utilized included cobimetinib (n=13) and trametinib (n=12). Among the response evaluable patients (n=23), ORR to MEKi treatment was 78% (9 CR, 9 PR, 4 SD, 1 PD). Among the 7 patients with liver involvement, responses were seen in 2 (29%) cases. ORR did not significantly differ according to mutation status among those with NGS data (78% MAPK mutated vs. 100% unmutated; p=1.0). In this subcohort, all of the 4 cases that did not respond to MEKi had liver involvement; 3 had BRAF deletions (2 SD and 1 PD), and one had MAPK1 mutation (SD). Median follow-up duration after MEKi initiation in the entire cohort was 18 months (95% CI 6 - 30). The median PFS and OS were not reached; 2-year PFS and OS were 78.1% and 79.9%, respectively (Figure 1A). The median PFS was much shorter in those with liver involvement (7 months [95% CI 0 - 14]) compared with those without liver disease (not reached [95% CI 19-not reached] P=0.047; Figure 1B). PFS did not differ significantly between MAPK pathway mutated and unmutated patients (p=0.34) Adverse events (AEs) were reported in 36% (n=9) and most commonly included rash (n=5) and fatigue (n=3). Four patients experienced grade 3-4 AEs including rash, fatigue, and thrombocytopenia. Common causes of MEKi discontinuation included AEs (n=3), progression (n=2), and drug holiday (n=2). At last follow-up, 5 patients died and 18 remained on MEKi. Death was attributable to LCH (n=3), concomitant malignancy (n=1), or unknown causes (n=1). Conclusions: In our multi-institutional study of adults with LCH, we found MEKi therapy to be highly efficacious. However, liver involvement correlated with a lack of response and worse PFS, while mutational status did not. Future studies are needed to evaluate optimum treatment for high-risk subgroups of LCH like liver disease.
Long-Term Outcomes with Single-Agent BRAF-Inhibitor Therapy in Erdheim-Chester Disease
Reiner, Anne S. , Bossert, Dana, Sigler, Allison , Buthorn, Justin J. , Rotemberg, Veronica , Rampal, Raajit K. , Reiner, Anne S , Goyal, Gaurav , Lacouture, Mario E. , Francis, Jasmine H. , Go, Ronald S. , Diamond, Eli L.

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 4557-4557

10.1182/blood-2023-184879 Get It

Introduction The treatment of Erdheim-Chester disease (ECD) has been revolutionized by the discovery of MAPK/ERK pathway mutations, most common being BRAF-V600E (50%). The US-FDA approved single-agent vemurafenib for BRAF-V600-mutated ECD in 2017 based on a phase II trial that included 22 patients with ECD and 4 with Langerhans cell histiocytosis (LCH), resulting in 100% overall response rate (ORR) by FDG-PET criteria (Diamond et al. JAMA Onc 2018). However, adverse events (AEs) to vemurafenib led to treatment interruption and/or dose modification in all patients, and drug discontinuation in 8 (31%) patients. Long-term outcomes and tolerability of BRAF-inhibitor (BRAFi) monotherapy in real world setting are unknown. In this study, we aimed to address these questions utilizing a large cohort of patients with ECD. Methods Registry-based ( NCT03329274) study of patients with ECD who received BRAFi (vemurafenib or dabrafenib) as any line of treatment. The registry captures detailed longitudinal clinical, treatment, and outcomes data through medical record abstraction. For this study, we focused on the events of discontinuation, dose reductions, and AEs to BRAFi therapy. Time-to-event analyses were conducted using Kaplan-Meier method from the date of initiation of BRAFi. Primary endpoint of the study was event-free survival (EFS), defined as time to progression of disease, discontinuation or alteration of therapy due to any cause (including addition of a MEK inhibitor), or death. Secondary endpoints included progression-free survival (PFS), defined as time to progression of disease or death, and overall survival (OS). Results We included 64 patients with ECD (including 7 with mixed ECD/LCH) in this study. Median age at diagnosis was 56y (range, 26-77) and at initiation of BRAFi was 57y (range, 26-77). Of these, 59 (92%) were BRAF-V600E, 2 (3.1%) were BRAF-wildtype, 1 had BRAF-V471F, 1 had BRAF-PICALM fusion, and 1 had unknown BRAF status. The distribution of organ involvement was bone (91%), neurologic (78%), brain parenchyma (62%), cardiovascular (58%), retroperitoneum (58%), skin (25%), and pulmonary (19%). BRAFi therapy was used as first-line in 38 (59.3%) and as subsequent line in the rest (median 1, range 1-7). The most common initial BRAFi used was vemurafenib (80%) followed by dabrafenib (20%). The median starting dose of vemurafenib was 720 mg bid (range 480-960) and end dose was 480mg bid (range, 240-480). The median start dose of dabrafenib was 100mg bid (range 50-150) and end dose was 50mg bid (range 50-100). Initial dose reduction of BRAFi was required due to AEs in 28 of 52 cases (54%) with final dose data available, encompassing cutaneous (43%), generalized symptoms or fatigue (18%), &gt;1 system affected (14%), lab abnormalities (11%), musculoskeletal (7%), and other (7%) toxicities. Of 60 patients with response data, a response was seen in 51 patients or 85% (42 partial response, 9 complete response, 8 stable disease, and 1 progressive disease). The median follow-up duration was 3.9 years (range 0.2-8.8). Single-agent BRAFi therapy was discontinued in 38 (59%) patients who received it initially (vemurafenib 63% vs. dabrafenib 46%, p=0.28). Reasons for discontinuation included AEs (n=20, 53%), addition of MEK-inhibitor (18%) for reducing cutaneous toxicities (n=5) or augment CNS response (n=2), disease progression (n=4, 11%), death (n=3, 8%), or others (n=4, 11%). 17 patients were rechallenged with a BRAFi after initial discontinuation, and 6 (35%) discontinued it again. The median EFS for the entire cohort from first BRAFi treatment was 2.99y (95% CI 1.6-4.8) and from second BRAFi was 2.82y (95% CI 1.19- not reached). The median PFS and OS were not reached, and 4 patients died at last follow-up (3 from ECD). Conclusions Almost 5 years after the FDA approval of vemurafenib for ECD, our real-world study from long-term follow-up of a large cohort of patients highlights high response rates, but at the cost of adverse events leading to dose reductions and treatment discontinuation in a large subset. Our results also highlight the entity of disease progression on BRAFi therapy. Our results underscore the importance of developing therapies that are efficacious and well-tolerated in this incurable disease.
P1105: NEUROLOGIC INVOLVEMENT IN ADULTS WITH ROSAI-DORFMAN DISEASE: CLINICAL PRESENTATION AND OUTCOMES
Medina, Aldo Acosta, Abeykoon, Jithma P. , Young, Jason R. , Go, Ronald S. , Diamond, Eli L. , Goyal, Gaurav

Mayo Clinic

HemaSphere | August 22, 2023 | Volume: 7 | Issue: S3 | Pages: e7029125

10.1097/01.hs9.0000971316.70291.25 Get It